PMHNP Exam Prep: High-Yield Topics on Psychopharmacology and Diagnosis for the NP Board Exam

The PMHNP exam loves questions that test whether you can keep patients safe, choose the next best step, and recognize high-yield patterns in psychopharmacology and diagnosis. This guide focuses on what comes up over and over—mechanisms, side effects that change management, monitoring that prevents harm, and diagnostic distinctions that steer treatment. For each point, you’ll see “why it matters” so you can reason through tricky stems, not just memorize facts.

Test Strategy: Think Safety, Then Sequence

When two answers look right, choose the one that reduces risk or confirms the diagnosis before treating. The exam rewards structured thinking:

• Safety first: Suicidality, severe agitation, delirium, withdrawal, pregnancy, and drug–drug interactions come before symptom control.
• Confirm, then treat: Order labs that change what you’d prescribe (e.g., TSH before labeling treatment-resistant depression; pregnancy test before valproate).
• Respect time-course: Medication effects and adverse events have timelines (e.g., serotonin syndrome in hours; NMS in days; clozapine myocarditis in the first month).
• Escalate logically: Optimize dose/duration → switch within class → switch class → augment → device-based therapy (TMS/ECT) for true nonresponse.

Antidepressants: What Changes Management

SSRIs (sertraline, escitalopram, fluoxetine, paroxetine, citalopram): First-line for depression/anxiety. Why: Best balance of efficacy and safety.

• Adverse effects: GI upset, sexual dysfunction, activation (akathisia-like). Why it matters: Activation can worsen anxiety early—dose low, go slow.
• QTc: Citalopram—avoid >40 mg/day (20 mg in older adults/hepatic impairment). Why: Torsades risk rises with dose and existing QT prolongation.
• Drug interactions: Fluoxetine and paroxetine are strong CYP2D6 inhibitors. Why: They raise levels of TCAs, antipsychotics, and some beta-blockers.

SNRIs (venlafaxine, duloxetine, desvenlafaxine): Good for depression with pain or GAD.

• BP rise (venlafaxine): Dose-related NE effect. Why: Monitor BP; if uncontrolled hypertension, choose an SSRI or duloxetine (less BP impact).
• Discontinuation: Venlafaxine has notable withdrawal. Why: Taper slowly to avoid flu-like symptoms and “brain zaps.”

Bupropion (NDRI): Activating; helps low energy and smoking cessation.

• Contraindications: Seizure disorder, eating disorders. Why: Lowers seizure threshold; risk is higher with electrolyte shifts in bulimia/anorexia.

Mirtazapine (NaSSA): Sedating, appetite-stimulating (especially at 7.5–15 mg). Why: Useful for insomnia and weight loss; move dose to bedtime.

TCAs: Effective but not first-line due to anticholinergic and cardiac risks.

• Overdose sign: QRS widening on ECG. Why: Risk of fatal arrhythmia; avoid in suicidal patients.

MAOIs: Phenelzine, tranylcypromine (for atypical depression).

• Tyramine restriction: Avoid aged cheeses, cured meats. Why: Hypertensive crisis risk.
• Washouts: 14 days between MAOI and SSRIs/SNRIs; 5 weeks after fluoxetine. Why: Long fluoxetine half-life; serotonin syndrome risk.

Augmentation strategies (treatment-resistant depression):

• Bupropion or mirtazapine: Mechanistic complement; improve energy or sleep/appetite.
• Liothyronine (T3): Speeds response even if TSH normal. Why: Central sensitization to monoamines.
• Lithium: Antisuicidal effect. Why: Good for recurrent depression with suicidality.
• Atypical antipsychotics: Aripiprazole, brexpiprazole, quetiapine. Why: Evidence-based augmentation in MDD.

Serotonin syndrome vs NMS:

• Serotonin syndrome: Hours; hyperreflexia/clonus, GI upset, diaphoresis, agitation. Treat with discontinuation, benzodiazepines, cyproheptadine, cooling.
• NMS: Days; lead-pipe rigidity, hyperthermia, high CK, autonomic instability. Treat with discontinuation, IV fluids, dantrolene or bromocriptine, ICU care.

Mood Stabilizers and Bipolar: What to Start and What to Check

Lithium: Gold standard for mania and maintenance; reduces suicide risk.

• Targets: Acute mania 0.8–1.2 mEq/L; maintenance 0.6–1.0. Toxicity usually >1.5; severe >2.0. Why: Narrow therapeutic window guides close monitoring.
• Baseline/monitoring: BMP, TSH, pregnancy test, consider ECG; level 5–7 days after dose change, then q3–6 months. Why: Renal and thyroid toxicity are dose-related and cumulative.
• Interactions: NSAIDs, ACE inhibitors/ARBs, and thiazides increase lithium. Why: They reduce renal clearance → toxicity risk.
• Pregnancy: Risk of Ebstein anomaly (first trimester); weigh risks/benefits; close level monitoring if continued.

Valproate: Acute mania, mixed states.

• Monitoring: LFTs, platelets; level 50–125 mcg/mL. Why: Hepatotoxicity, thrombocytopenia, pancreatitis can be fatal.
• Pregnancy: Strong teratogen (neural tube defects, cognitive effects). Why: Avoid in women of childbearing potential unless no alternatives.
• Hyperammonemia: Consider if lethargy/encephalopathy; treat with lactulose/carnitine.

Carbamazepine: Mania, especially with aggression or dyscontrol.

• Monitoring: CBC (agranulocytosis, aplastic anemia), sodium (SIADH), LFTs; level 4–12 mcg/mL. Why: Potentially life-threatening cytopenias and hyponatremia.
• Genetics: HLA-B*1502 (Asians) for SJS/TEN; HLA-A*3101 (some Europeans). Why: Screen high-risk groups before starting.
• Autoinduction/CYP3A4 inducer: Lowers levels of many drugs (including oral contraceptives). Why: Contraceptive failure risk.

Lamotrigine: Bipolar depression; not effective for acute mania.

• Rash risk: Titrate slowly; higher with valproate. Why: Prevent SJS/TEN; stop at first sign of rash unless clearly benign.
• Pregnancy: Generally safer mood stabilizer; dose may need increase due to clearance.

Acute treatment choice:

• Acute mania: Lithium or valproate + antipsychotic (e.g., risperidone, olanzapine). Why: Combo speeds stabilization.
• Bipolar depression: Lamotrigine, quetiapine, lurasidone, or lithium. Why: Avoid antidepressant monotherapy due to switch risk.

Antipsychotics: Efficacy, EPS, Metabolic Risk, and Clozapine Rules

FGAs vs SGAs: FGAs more EPS; SGAs more metabolic effects (olanzapine highest). Choose based on patient risks.

• EPS management:
  • Acute dystonia: IM benztropine or diphenhydramine (rapid relief).
  • Akathisia: Propranolol first-line; benzodiazepine second-line.
  • Parkinsonism: Benztropine or amantadine; avoid antipsychotic dose increases.
  • Tardive dyskinesia: Switch to clozapine or add VMAT2 inhibitor (valbenazine, deutetrabenazine).
• Prolactin: Risperidone/paliperidone increase; aripiprazole can lower. Why: Choose aripiprazole if hyperprolactinemia symptoms.
• QTc: Ziprasidone, iloperidone, thioridazine highest risk. Avoid if QTc ≥500 ms or major risk factors. Why: Torsades prevention.
• Metabolic monitoring (all SGAs): Weight/BMI, waist, BP, fasting glucose/A1c, lipids at baseline, 3 months, then periodically. Why: Early detection prevents long-term harm.

Clozapine: For treatment-resistant schizophrenia or suicidality.

• ANC rules: Baseline ANC ≥1500/µL (≥1000 in BEN). Monitor weekly first 6 months; q2 weeks next 6 months; monthly thereafter. Interrupt if ANC <1000; urgent eval if <500. Why: Agranulocytosis risk is time-dependent and dose-related.
• Other risks: Myocarditis (first month—fever, chest pain, troponin elevation), seizures (dose-related), sialorrhea, severe constipation/ileus (can be fatal). Why: Proactive bowel regimen and early cardiac monitoring save lives.
• Smoking: Nicotine smoke induces CYP1A2 → lowers clozapine levels; stopping smoking raises levels. Why: Adjust dose with smoking changes.

Anxiolytics and Sleep: Relief Without Creating New Problems

Benzodiazepines: Short-term for severe anxiety or catatonia; avoid in SUD, COPD/OSA, or with opioids. Why: Dependence and respiratory depression risks.

Buspirone: Non-sedating, non-addictive for GAD; takes weeks. Why: Good for patients at risk for misuse.

Hydroxyzine: PRN anxiolytic; sedating antihistamine. Why: Useful bridge while SSRI/SNRI takes effect.

Propranolol: Performance anxiety. Why: Controls autonomic symptoms; avoid in asthma or bradycardia.

Insomnia: Start with CBT-I. Pharmacologic options:

• Zolpidem/z-drugs: Boxed warning for complex sleep behaviors; next-day sedation. Why: Use lowest effective dose; avoid in older adults.
• Doxepin (3–6 mg): Sleep maintenance; minimal anticholinergic at low dose. Why: Safer than TCAs at antidepressant doses.
• Trazodone: Sedation, orthostasis; rare priapism. Why: Caution in older adults and those on antihypertensives.
• Orexin antagonists (suvorexant/lemborexant): Good for sleep onset/maintenance; watch next-day somnolence.
• Ramelteon: Safe in older adults; no abuse potential.

Stimulants and ADHD: Efficacy With Safeguards

First-line: Methylphenidate or amphetamines. Monitor BP, HR, weight, sleep, and misuse/diversion.

• Contraindications: Symptomatic cardiovascular disease, uncontrolled hypertension, active psychosis. Why: Stimulants can worsen these conditions.
• Psychiatric effects: Can precipitate mania or psychosis. Why: Screen for bipolar and psychosis history before starting.
• Non-stimulants: Atomoxetine (watch liver injury, suicidality warnings), guanfacine/clonidine (sedation, hypotension). Why: Use when stimulants aren’t tolerated or misuse risk is high.

Substance-Related Disorders: Recognize, Stabilize, Treat

• Alcohol withdrawal: Timeline: tremor/anxiety (6–24h), seizures (24–48h), delirium tremens (48–96h). Treat with benzodiazepines; give thiamine before glucose. Why: Prevent Wernicke’s encephalopathy and seizures.
• Opioid intoxication/overdose: Miosis, respiratory depression—give naloxone. Withdrawal: lacrimation, yawning, piloerection—treat with buprenorphine or methadone; clonidine for symptoms. Why: MAT reduces mortality.
• Stimulant intoxication: Mydriasis, tachycardia, chest pain, psychosis—benzodiazepines first-line; avoid pure beta-blockers with cocaine due to unopposed alpha.
• Benzodiazepine withdrawal: Anxiety, tremor, seizures—taper slowly with a long-acting benzo. Why: Rapid reversal (flumazenil) can precipitate seizures.

Diagnostic High-Yield: Patterns That Guide Treatment

• MDD vs bipolar depression: Bipolar clues: early onset, postpartum episodes, family history of bipolar, antidepressant-induced activation, atypical features. Why: Avoid antidepressant monotherapy if bipolar is likely.
• Schizophrenia spectrum:
  • Schizophrenia: ≥6 months with functional decline.
  • Schizophreniform: 1–6 months.
  • Brief psychotic disorder: 1 day–1 month.
  • Schizoaffective: Mood episodes present for the majority of illness + 2 weeks psychosis without mood symptoms. Why: Antipsychotic ± mood stabilizer, not antidepressant alone.
  • Delusional disorder: Fixed delusion ≥1 month, relatively preserved function, minimal hallucinations.
• Panic disorder vs GAD: Panic: discrete surges with fear of next attack; GAD: chronic worry ≥6 months with physical tension. Why: CBT and SSRIs help both; avoid PRN benzos as sole therapy.
• PTSD vs acute stress disorder: ASD is <30 days after trauma; PTSD ≥1 month. Why: SSRIs/SNRIs and trauma-focused therapy are key; prazosin for nightmares.
• OCD: Intrusive, ego-dystonic thoughts; compulsions to reduce distress. Why: High-dose SSRIs or clomipramine + exposure/response prevention.
• Delirium vs dementia: Delirium = acute attention/awareness disturbance with fluctuating course; dementia (major neurocognitive disorder) = chronic progressive deficits. Why: Delirium is a medical emergency; identify triggers (infection, meds).
• Borderline personality vs bipolar: Borderline mood shifts are rapid and reactive to interpersonal stress; bipolar mood episodes last days–weeks with neurovegetative changes. Why: Prevent mislabeling and overtreatment with mood stabilizers.
• Malingering vs factitious: Malingering = external gain; factitious = psychological need to assume sick role. Why: Approach with documentation and limit-setting, not confrontation.
• Adult ADHD vs anxiety/depression: ADHD starts in childhood, cross-situational impairment, persistent. Why: Collateral and school records support diagnosis.

Suicide Risk: What Changes the Disposition

• High-risk features: Current intent/plan, access to lethal means, past attempts (especially violent), recent losses, severe hopelessness, intoxication, psychosis (command hallucinations), akathisia. Why: These increase short-term risk.
• Next steps: Remove means, involve supports, safety planning, rapid follow-up, or hospitalization if imminent risk or lack of protective factors. Why: Level of care must match risk.

Special Populations: Kids, Older Adults, Pregnancy/Lactation

Children/adolescents:

• Depression: Fluoxetine first-line; SSRIs carry suicidality warning up to age 24—close monitoring early in treatment. Why: Activation can precede mood improvement.
• ADHD: Track height/weight, sleep, and appetite with stimulants; consider non-stimulants if tics, anxiety, or misuse risk.

Older adults:

• Start low, go slow: Reduced clearance and higher sensitivity to side effects. Why: Prevent falls, delirium, and orthostasis.
• Avoid anticholinergics: Amitriptyline, benztropine, diphenhydramine. Why: Cognitive impairment, urinary retention, constipation.
• Antipsychotics in dementia psychosis: Boxed warning for mortality. Why: Use only if severe symptoms or danger; document risk–benefit.

Pregnancy/lactation:

• SSRIs: Generally acceptable; avoid paroxetine in first trimester if possible. Sertraline favored in lactation. Why: Best reproductive safety data.
• Lithium: Use with caution; monitor levels closely due to volume shifts. Why: Narrow window; neonatal toxicity risk near delivery.
• Valproate and carbamazepine: Teratogenic (neural tube defects). Why: Avoid if possible, especially first trimester.
• Lamotrigine: Often preferred mood stabilizer; adjust dose as clearance increases in pregnancy. Why: Relatively favorable safety profile.
• Benzodiazepines: Use sparingly; risk of floppy infant and withdrawal. Why: Neonatal respiratory and tone concerns.

Labs, Monitoring, and Drug–Drug Interactions You’ll Be Asked About

• Before antidepressants: TSH (hypothyroidism mimics depression), pregnancy if relevant, ECG if QT risk (citalopram, ziprasidone, methadone).
• Before antipsychotics: Weight/BMI, waist, BP, A1c/glucose, lipids; prolactin if symptomatic. Consider ECG for QT-prolonging agents.
• Lithium: BMP, TSH, pregnancy, consider ECG; monitor levels regularly.
• Valproate: LFTs, CBC with platelets; drug level.
• Carbamazepine: CBC, LFTs, sodium; consider HLA testing; drug level.
• Lamotrigine: No routine labs; educate on rash and slow titration.
• CYP interactions:
  • Fluoxetine/paroxetine (CYP2D6 inhibitors) raise TCA and antipsychotic levels.
  • Fluvoxamine (CYP1A2/2C19 inhibitor) raises clozapine and benzodiazepines.
  • Carbamazepine (CYP3A4 inducer) lowers many drugs, including oral contraceptives.
  • Valproate raises lamotrigine levels (halve lamotrigine dose).
  • Smoking induces CYP1A2 → lowers clozapine/olanzapine; stopping smoking increases levels.
  • Grapefruit inhibits CYP3A4 → increases quetiapine, carbamazepine, buspirone. Why: Toxicity risk.

Rapid and Somatic Treatments: When Meds Aren’t Enough

• ECT: Severe depression (especially with psychosis or suicidality), catatonia, treatment-resistant mania, and during pregnancy when rapid response is needed. Why: Fastest, most effective option for life-threatening illness.
• TMS: Treatment-resistant depression without anesthesia or cognitive effects. Why: Good for patients who fail meds but don’t need ECT speed.
• Ketamine/esketamine: Rapid antidepressant effect with dissociation and transient BP elevation. Why: Bridge in acute suicidality; monitor closely.
• Cataonia pearls: Lorazepam challenge first; ECT if refractory. Why: Mortality rises if untreated.

Common Exam Traps and How to Avoid Them

• Starting SSRIs in unrecognized bipolar depression: Always ask about mania/hypomania and family history before initiating.
• Giving bupropion in bulimia or seizure disorder: Choose an SSRI instead (fluoxetine is best for bulimia at 60 mg/day).
• Missing medical mimics: Hypothyroidism, anemia, B12 deficiency, sleep apnea. Get targeted labs before declaring treatment resistance.
• MAOI interactions: Avoid with SSRIs/SNRIs, dextromethorphan, linezolid, meperidine, and tramadol. Observe required washouts.
• QTc risk stacking: Don’t combine multiple QT-prolonging drugs in a patient with baseline QTc >500 ms or major risk factors.
• Propranolol in asthma: Use alternatives (e.g., benzodiazepine for performance anxiety if low misuse risk).
• Antipsychotics for behavioral symptoms of dementia without severe distress or danger: Try nonpharmacologic strategies first; document risk–benefit if you must use them.
• Ignoring weight gain/metabolic signals: Switch from olanzapine to lower-risk agents (ziprasidone, lurasidone, aripiprazole) when metabolic markers worsen.
• Not addressing means in suicidal patients: Lethal means counseling is a treatment, not just documentation.

Mini Case Walk-Throughs

• Case 1: 24-year-old with panic attacks, daily alcohol use, asks for alprazolam.
  
  Best next step: Treat alcohol use first and start SSRI/SNRI with psychotherapy; avoid benzos due to SUD risk.
• Case 2: 42-year-old on lithium with new tremor and diarrhea; taking ibuprofen for back pain.
  
  Why it matters: NSAIDs increase lithium levels. Check level/BMP, hold lithium if elevated, switch to acetaminophen for pain.
• Case 3: 33-year-old with depression on sertraline develops agitation, hyperreflexia, and clonus after starting linezolid for pneumonia.
  
  Diagnosis: Serotonin syndrome. Stop serotonergic agents, give benzodiazepines, consider cyproheptadine.
• Case 4: 72-year-old with insomnia and falls on diphenhydramine.
  
  Fix: Stop anticholinergic; start CBT-I; consider ramelteon or low-dose doxepin instead.
• Case 5: 29-year-old with treatment-resistant schizophrenia; two antipsychotic failures.
  
  Next step: Start clozapine with ANC monitoring; counsel on constipation prophylaxis and smoking effects on dosing.

Final Takeaways

• Choose treatments that reduce immediate risk first; confirm diagnoses with targeted labs when results change management.
• Know the few numbers that matter: lithium levels/monitoring, valproate and carbamazepine labs, clozapine ANC rules, citalopram dose limits, QTc ≥500 ms red flag.
• Distinguish look-alikes: bipolar vs MDD, serotonin syndrome vs NMS, delirium vs dementia, schizoaffective vs schizophrenia.
• For special populations, default to the safest effective option and document risk–benefit clearly.

If you practice thinking “what’s most likely, what’s most dangerous, and what changes my choice,” you’ll see the right answer faster—and keep patients safer in real life.

G S Sachin

I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.

Mail- Sachin@pharmacyfreak.com